Paul E. Stang, PhD; Patrick B. Ryan, MEng; Judith A. Racoosin, MD, MPH; J. Marc Overhage, MD, PhD; Abraham G. Hartzema, PharmD, MSPH, PhD; Christian Reich, MD, PhD; Emily Welebob, RN, MS; Thomas Scarnecchia, MS; Janet Woodcock, MD
The U.S. Food and Drug Administration (FDA) Amendments Act of 2007 mandated that the FDA develop a system for using automated health care data to identify risks of marketed drugs and other medical products. The Observational Medical Outcomes Partnership is a public–private partnership among the FDA, academia, data owners, and the pharmaceutical industry that is responding to the need to advance the science of active medical product safety surveillance by using existing observational databases. The Observational Medical Outcomes Partnership's transparent, open innovation approach is designed to systematically and empirically study critical governance, data resource, and methodological issues and their interrelationships in establishing a viable national program of active drug safety surveillance by using observational data. This article describes the governance structure, data-access model, methods-testing approach, and technology development of this effort, as well as the work that has been initiated.
Stang PE, Ryan PB, Racoosin JA, et al. Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153:600–606. doi: https://doi.org/10.7326/0003-4819-153-9-201011020-00010
Download citation file:
Published: Ann Intern Med. 2010;153(9):600-606.
Research and Reporting Methods.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use